Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain
Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement thi...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2024-12-01
|
| Col·lecció: | Human Vaccines & Immunotherapeutics |
| Matèries: | |
| Accés en línia: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|